Shots:

• The designation is based on the data from an ongoing SCarlet RoAD- Marguerite RoAD OLE trials along with other studies evaluating gantenerumab (anti-amyloid beta Ab) in patients with AD- demonstrated a reduction in brain amyloid plaque
• The studies have been included in the optimized design of two ongoing P-III trials- GRADUATE 1 & 2 that evaluates the effects- safety & efficacy of gantenerumab (1020mg) vs PBO in 2-000 patients with early AD across ~350 study centers in 30+ countries globally. The results are expected in H2’22
• The company continues to explore multiple approaches and molecules for the treatment of AD & support clinicians to monitor disease progression

  | Ref: Genentech | Image: Xconomy